Download MendeleyExploring the plasticity of the InhA substrate-binding site using new diaryl ether inhibitors.
Tamhaev, R., Grosjean, E., Ahamed, H., Chebaiki, M., Rodriguez, F., Recchia, D., Degiacomi, G., Pasca, M.R., Maveyraud, L., Mourey, L., Lherbet, C.(2023) Bioorg Chem 143: 107032-107032
- PubMed: 38128204
- DOI: https://doi.org/10.1016/j.bioorg.2023.107032
- Primary Citation of Related Structures:
8OTL - PubMed Abstract:
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a worldwide scourge with more than 10 million people affected yearly. Among the proteins essential for the survival of Mtb, InhA has been and is still clinically validated as a therapeutic target. A new family of direct diaryl ether inhibitors, not requiring prior activation by the catalase peroxidase enzyme KatG, has been designed with the ambition of fully occupying the InhA substrate-binding site. Thus, eleven compounds, featuring three pharmacophores within the same molecule, were synthesized. One of them, 5-(((4-(2-hydroxyphenoxy)benzyl)(octyl)amino)methyl)-2-phenoxyphenol (compound 21), showed good inhibitory activity against InhA with IC 50 of 0.70 µM. The crystal structure of compound 21 in complex with InhA/NAD + showed how the molecule fills the substrate-binding site as well as the minor portal of InhA. This study represents a further step towards the design of new inhibitors of InhA.
Organizational Affiliation:
Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (LSPCMIB), UMR 5068, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France.
